Treatment of pathologies associated with overproduction of o
GenKyoTex S.A.
Incorporated
01.02.2006Headquarters
Plan-Les-OuatesSupport
This firm, founded in 2006 by scientists from Switzerland, the USA and Japan, is in the midst of a significant step. In May, GenKyoTex announced the closing of a round of financing worth more than 18 million Swiss francs. These funds will allow the start of clinical trials of its first drug before this year is out.
www.genkyotex.com
News
Calliditas Therapeutics to acquire Genkyotex for €88 million (startupticker.ch)
Eclosion: Incubator for market stars in Geneva (startupticker.ch)
GenKyoTex now listed on Euronext (startupticker.ch)
Genkyotex to merge with a French public biotech company (startupticker.ch)
Genkyotex’s lead product granted Orphan Drug Designation (startupticker.ch)
Genkyotex announces Top-Line results of Phase 2 Clinical Program (startupticker.ch)
Genkyotex Raises CHF 20 Million and Considers IPO (startupticker.ch)
Genkyotex’s clinical trial on track (startupticker.ch)
Experienced pharma professionals join Genkyotex (startupticker.ch)
Genkyotex Lead Product Successfully Shown to Halt Diabetic Kidney Disease (startupticker.ch)
Genkyotex’ Lead Product Shows Promise in Osteoporosis (startupticker.ch)
Genkyotex Receives Approval for Phase II Clinical Study (startupticker.ch)
Genkyotex Drug Reduces Atherosclerosis Development (startupticker.ch)
Genkyotex presents excellent Phase I Data (startupticker.ch)
Genkyotex Raises CHF25 Million (startupticker.ch)
First compound of Genkyotex enters clinical trials (startupticker.ch)